None of them were successful trials.
The FDA understands the statistical issues with post hoc analysis being used to draw conclusions.
Let's see how it pans out over the next few months.
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-115
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.87 |
Change
0.000(0.00%) |
Mkt cap ! $3.662B | |||
| Open | High | Low | Value | Volume |
| $2.83 | $2.92 | $2.82 | $8.136M | 2.838M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1645 | $3.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.59 | 32012 | 1 |
View Market Depth
| Last trade - 15.59pm 28/01/2025 (20 minute delay) ? |
| MSB (ASX) Chart |